Although current clinical trials have not yet demonstrated satisfactory results for HIF-1α inhibitors as monotherapy in breast cancer treatment, with continuous and in-depth research on the role of HIF-1α in cancer development, it is believed that targeted HIF-1α therapeutics will bring new hope to breast cancer patients in the near future. This evidence concerns the gene HIF1A and breast carcinoma.